MX2019012385A - Administración parenteral no sistémica de agentes amortiguadores para inhibir la metástasis de tumores sólidos, hiperpigmentación y gota. - Google Patents

Administración parenteral no sistémica de agentes amortiguadores para inhibir la metástasis de tumores sólidos, hiperpigmentación y gota.

Info

Publication number
MX2019012385A
MX2019012385A MX2019012385A MX2019012385A MX2019012385A MX 2019012385 A MX2019012385 A MX 2019012385A MX 2019012385 A MX2019012385 A MX 2019012385A MX 2019012385 A MX2019012385 A MX 2019012385A MX 2019012385 A MX2019012385 A MX 2019012385A
Authority
MX
Mexico
Prior art keywords
gout
solid tumors
hyperpigmentation
buffering agents
systemic administration
Prior art date
Application number
MX2019012385A
Other languages
English (en)
Inventor
Bruce J Sand
Original Assignee
Ampersand Biopharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ampersand Biopharmaceuticals Llc filed Critical Ampersand Biopharmaceuticals Llc
Publication of MX2019012385A publication Critical patent/MX2019012385A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La dosificación parenteral (distinta de la dosificación sistémica directa) del aumento del pH y otros agentes antimetastásicos solos o combinados es eficaz y supera las desventajas de la administración intravenosa y oral en el tratamiento contra tumores sólidos, melasma y gota.
MX2019012385A 2017-04-17 2018-04-17 Administración parenteral no sistémica de agentes amortiguadores para inhibir la metástasis de tumores sólidos, hiperpigmentación y gota. MX2019012385A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762602227P 2017-04-17 2017-04-17
US201762602358P 2017-04-20 2017-04-20
US201762602359P 2017-04-20 2017-04-20
US201762559360P 2017-09-15 2017-09-15
US201762559947P 2017-09-18 2017-09-18
US201762562725P 2017-09-25 2017-09-25
US201762609982P 2017-12-22 2017-12-22
US201862639904P 2018-03-07 2018-03-07
PCT/US2018/028017 WO2018195111A1 (en) 2017-04-17 2018-04-17 Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout

Publications (1)

Publication Number Publication Date
MX2019012385A true MX2019012385A (es) 2022-03-15

Family

ID=63856054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012385A MX2019012385A (es) 2017-04-17 2018-04-17 Administración parenteral no sistémica de agentes amortiguadores para inhibir la metástasis de tumores sólidos, hiperpigmentación y gota.

Country Status (7)

Country Link
EP (1) EP3612274A4 (es)
JP (1) JP2020516690A (es)
KR (1) KR20200042440A (es)
CN (1) CN111093774A (es)
AU (3) AU2018255294B2 (es)
MX (1) MX2019012385A (es)
WO (1) WO2018195111A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4349414A2 (en) 2014-12-23 2024-04-10 Dyve Biosciences, Inc. Methods and formulations for transdermal administration
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents
US20190201327A1 (en) * 2017-09-25 2019-07-04 Ampersand Biopharmaceuticals, Inc. Topical applications of withaferin a
WO2020086766A1 (en) * 2018-10-23 2020-04-30 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of dermal contouring agents
EP3906059A4 (en) * 2018-11-02 2022-06-22 Ampersand Biopharmaceuticals, Inc. MANAGING THE RISK OF CATION OVERLOAD AND ELECTROLYTE BALANCE WITH TOPICALLY APPLIED BUFFER
US20210059955A1 (en) * 2019-08-26 2021-03-04 RL Patents, LLC Systems and methods for decrystallization of uric acid
US20230330041A1 (en) * 2020-08-27 2023-10-19 Beijing Changsheng Pharmaceutical Technology Co., Ltd. Application of tris (hydroxymethyl) aminomethane pharmaceutically acceptable salt to drugs for treating hyperuricemia
CN113181149A (zh) * 2021-06-11 2021-07-30 北京畅盛医药科技有限公司 一种治疗痛风性关节炎的皮肤外用药物制剂
CN116539880B (zh) * 2022-12-05 2023-12-08 四川大学华西医院 检测代谢物和/或组织蛋白的试剂在制备痛风性关节炎筛查试剂盒中的用途
CN116284814A (zh) * 2023-01-17 2023-06-23 杭州三式化妆品有限公司 超分子传明酸甘醇酸离子盐及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176918A (en) * 1990-12-20 1993-01-05 Jones Jeffry L Topical medicament
ATE212549T1 (de) * 1996-04-04 2002-02-15 Hoffmann La Roche Verwendung von tetrahydrobetacarbolin-derivaten zur vorbeugung der metastasenbildung
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20030228374A1 (en) * 2002-06-07 2003-12-11 Pesacreta Thomas C. Topical treatment for skin irritation
AU2002950308A0 (en) * 2002-07-23 2002-09-12 Phoenix Eagle Company Pty Ltd Topically applied composition
CA2645073A1 (en) * 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
US20110230551A1 (en) * 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
CN101897784A (zh) * 2009-05-27 2010-12-01 北京因科瑞斯医药科技有限公司 一种用于痛风的中药组合物及其制备方法
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
WO2011066379A2 (en) * 2009-11-24 2011-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. METHOD OF REDUCING INTRATUMORAL pHe AND ACID-MEDIATED INVASION
WO2012064429A2 (en) * 2010-11-09 2012-05-18 The Regents Of The University Of California Skin permeating and cell entering (space) peptides and methods of use thereof
RU2593848C2 (ru) * 2011-03-29 2016-08-10 Неокемир Инк. Противоопухолевое средство, содержащее диоксид углерода в качестве активного ингредиента
US9266815B2 (en) * 2012-03-28 2016-02-23 University Of Central Florida Research Foundation, Inc. Anti-metastatic agents predicated upon polyamine macrocyclic conjugates
EP4349414A2 (en) * 2014-12-23 2024-04-10 Dyve Biosciences, Inc. Methods and formulations for transdermal administration
CN106236937A (zh) * 2016-08-31 2016-12-21 腾冲恒益东山休闲度假有限责任公司 能缓解痛风性关节炎的泡浴液

Also Published As

Publication number Publication date
JP2020516690A (ja) 2020-06-11
AU2018255294A1 (en) 2019-12-05
AU2023254920A1 (en) 2023-11-16
EP3612274A4 (en) 2021-05-26
AU2022241559A1 (en) 2022-10-27
CN111093774A (zh) 2020-05-01
AU2022241559B2 (en) 2023-07-27
KR20200042440A (ko) 2020-04-23
AU2018255294B2 (en) 2022-07-28
EP3612274A1 (en) 2020-02-26
WO2018195111A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
MX2019012385A (es) Administración parenteral no sistémica de agentes amortiguadores para inhibir la metástasis de tumores sólidos, hiperpigmentación y gota.
MX2021014509A (es) Composiciones farmaceuticas que comprenden meloxicam.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
IL279036A (en) Pharmaceutical combination, the composition and preparation of a combination containing an activator of glucokinase and an inhibitor of SGLT-2, preparation methods and their uses
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2022004374A (es) Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MY191574A (en) Pharmaceutical compositions comprising meloxicam
MX2016008362A (es) Combinaciones farmaceuticas.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2021004308A (es) Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
MX2021001376A (es) Carboxamidas como inhibidores de proteasa específicos de ubiquitina.
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
UA117581C2 (uk) Протипухлинний лікарський засіб, який включає низькодозований гідрохлориду іринотекану гідрат
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
MX2019014771A (es) Inhibidores de la proteína -1 de adhesión vascular para uso en la prevención o tratamiento de migraña.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MY170451A (en) A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
MX2019007115A (es) Proteina recombinante uk 114 novedosa en forma de polimero estable para uso en el tratamiento, diagnostico y prevencion de tumores solidos y sistemicos malignos.
MX2018013568A (es) Composiciones de suministro gastrico flotante de zinc.